|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
52,373,000 |
Market
Cap: |
2.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$30.85 - $52.9 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 474 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
126,152 |
256,428 |
308,234 |
348,833 |
Total Sell Value |
$5,873,218 |
$11,298,513 |
$13,114,420 |
$14,216,679 |
Total People Sold |
4 |
7 |
7 |
7 |
Total Sell Transactions |
9 |
26 |
34 |
37 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Colangelo Dominick |
President and CEO |
|
2024-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
177,485 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2024-02-12 |
4 |
D |
$47.42 |
$36,751 |
D/D |
(775) |
53,984 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2024-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,625 |
54,759 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2024-02-12 |
4 |
D |
$47.42 |
$84,502 |
D/D |
(1,782) |
2,667 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2024-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
4,449 |
|
- |
|
Zerbe Robert L Md |
|
|
2024-01-29 |
4 |
AS |
$44.22 |
$101,706 |
D/D |
(2,300) |
23,395 |
|
-0% |
|
Zerbe Robert L Md |
|
|
2024-01-25 |
4 |
AS |
$44.02 |
$8,804 |
D/D |
(200) |
25,695 |
|
10% |
|
Zerbe Robert L Md |
|
|
2024-01-22 |
4 |
AS |
$41.39 |
$334,775 |
D/D |
(8,000) |
25,895 |
|
13% |
|
Zerbe Robert L Md |
|
|
2024-01-22 |
4 |
OE |
$4.12 |
$12,360 |
D/D |
3,000 |
28,895 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-01-18 |
4 |
AS |
$38.58 |
$645,289 |
D/D |
(16,726) |
169,985 |
|
19% |
|
Colangelo Dominick |
President and CEO |
|
2024-01-18 |
4 |
OE |
$3.02 |
$50,513 |
D/D |
16,726 |
186,711 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2024-01-17 |
4 |
AS |
$37.97 |
$635,086 |
D/D |
(16,726) |
169,985 |
|
27% |
|
Colangelo Dominick |
President and CEO |
|
2024-01-17 |
4 |
OE |
$3.02 |
$50,513 |
D/D |
16,726 |
186,711 |
|
- |
|
Zerbe Robert L Md |
|
|
2024-01-12 |
4 |
AS |
$38.09 |
$83,798 |
D/D |
(2,200) |
30,895 |
|
26% |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-12-14 |
4 |
S |
$37.45 |
$3,970 |
D/D |
(106) |
4,467 |
|
-24% |
|
Colangelo Dominick |
President and CEO |
|
2023-12-14 |
4 |
AS |
$37.12 |
$445,440 |
D/D |
(12,000) |
169,985 |
|
24% |
|
Colangelo Dominick |
President and CEO |
|
2023-12-14 |
4 |
OE |
$3.57 |
$42,840 |
D/D |
12,000 |
181,985 |
|
- |
|
Wotton Paul K |
|
|
2023-12-14 |
4 |
S |
$37.31 |
$186,550 |
D/D |
(5,000) |
26,802 |
|
-24% |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-12-13 |
4 |
S |
$34.20 |
$48,974 |
D/D |
(1,432) |
4,573 |
|
-28% |
|
Colangelo Dominick |
President and CEO |
|
2023-12-13 |
4 |
AS |
$34.03 |
$408,360 |
D/D |
(12,000) |
169,985 |
|
28% |
|
Colangelo Dominick |
President and CEO |
|
2023-12-13 |
4 |
OE |
$3.57 |
$42,840 |
D/D |
12,000 |
181,985 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-12-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,757 |
169,985 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-12-07 |
4 |
AS |
$33.84 |
$406,080 |
D/D |
(12,000) |
176,742 |
|
28% |
|
Colangelo Dominick |
President and CEO |
|
2023-12-07 |
4 |
OE |
$3.57 |
$42,840 |
D/D |
12,000 |
188,742 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-12-06 |
4 |
AS |
$34.43 |
$426,829 |
D/D |
(12,397) |
176,742 |
|
30% |
|
402 Records found
|
|
Page 3 of 17 |
|
|